Pharmacology of the immune system drugs

Frage	Antworten
Fostamatinib R343	Syk inhibitors
Rilonacept	IL-1 trap (FOAS)
Anakinra	Recombinant IL-1ra
Pralnacasan	ICE inhibitor (oral)
Verciniron	CCR9 blocker - Tc in gut for chromes
Marimastat	TACE/MMP inhibitor (MS SE)
NFkB inhibitors for TNFa	glucocorticoids thalidomide curcumin
Ertanercept	TNFR Ab fusion protein
Rituximab MEDI-155	CD20 on Bc
Zieluton	inhibits leukotrienes
Infliximab	anti-TNF mAb (hu Fc & mu Fv)
Adalimumab	Fully hu anti-TNF
certolizumab pegol	PEGylated Fab fragment of TNFa
PEGylation	↑ stability ↓ renal clearnace
Drawbacks of immunotherapy for TNFa	- immunogenic (∴ humanise) - short plasma T1/2 (∴ PEG) - need to IV admin - Infection risks (latent TB) - expensive
Onercept	PEG TNF binding protein (discontinued)
Ruxolitinib	JAK 1/2 inhibitor
Tofacitinib	Orally active JAK inhibitor (RA w/ MTX)
nedocromil	sodium cromoglycate topical for nose & eyes Mast cell stablaliser: inhibit mediator release only effective in 50% of population but treats early and late phase asthma
prednisolone budsonide	inhibits NFkB ∴ leuk migration via chemotaxis glucocorticoids
Altrakincept	soluable recombinant IL-4 dissapointing PIII
Pitrakinra	IL-4 variant ↓ late phase responses
Librikizumab	anti-IL-13 mAb effects secretion of epithelium only really helps FEV1 improvements
Ustekinumab	hu mAb
ketotifen	H1 antagonist & mast cell stabliser opthalmic and oral also leukotriene and PDE antagonist Maybe H4 activity: chemotaxis
Omalizumab	anti-IgE for allergic athmatics: NICE in sterioid resistants binds Fc needs to be taken for a while and expensive
anti-IL-4	Altrakincept: soluable recombinant IL-4 receptor Pitrakinra: IL-4 variant
Lebrikizumab	IL-13 mAb effects secretion of epithelium
Mepolizumab	anti-IL5 for eosinophilic dermatis
Braikinumab	IL-12/23 mAb

Nächster

Pharmacology of the immune system drugs

Beschreibung

Zusammenfassung der Ressource

ähnlicher Inhalt

	Erstellt von Livvi Harris vor mehr als 10 Jahre